NCT05736367View on ClinicalTrials.gov

Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2028

Conditions
Breast Cancer
Interventions
DRUG

U-13C-glucose

Discover new insights into the glucose, TCA cycle, amino acid, and lipid metabolic dependencies of HR+/Her2- breast cancer, via liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo U-13C-glucose-labeled biopsy of tumor and benign adjacent tissue

Trial Locations (2)

08903

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

NOT_YET_RECRUITING

RWJBarnabas Health, New Brunswick

Sponsors
All Listed Sponsors
collaborator

Ludwig Institute for Cancer Research

OTHER

lead

Rutgers, The State University of New Jersey

OTHER